Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis | 17 | 2024 | 32 | 10.010 |
Why?
|
| Dermatomyositis | 3 | 2024 | 12 | 1.930 |
Why?
|
| Sarcoidosis | 2 | 2020 | 13 | 1.260 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2024 | 490 | 1.080 |
Why?
|
| Rheumatology | 5 | 2024 | 70 | 0.950 |
Why?
|
| Humans | 29 | 2024 | 22848 | 0.890 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2024 | 5 | 0.870 |
Why?
|
| Polymyositis | 1 | 2023 | 8 | 0.860 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 177 | 0.830 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 40 | 0.820 |
Why?
|
| Vasculitis, Central Nervous System | 2 | 2020 | 7 | 0.810 |
Why?
|
| Fitness Trackers | 1 | 2022 | 9 | 0.790 |
Why?
|
| Adult | 12 | 2024 | 6584 | 0.780 |
Why?
|
| Myocarditis | 1 | 2022 | 8 | 0.770 |
Why?
|
| Myasthenia Gravis | 1 | 2022 | 31 | 0.760 |
Why?
|
| Muscle Strength | 2 | 2023 | 104 | 0.730 |
Why?
|
| Muscle Weakness | 1 | 2021 | 27 | 0.720 |
Why?
|
| Osteoporosis | 1 | 2022 | 69 | 0.710 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 539 | 0.700 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2020 | 4 | 0.700 |
Why?
|
| Neoplasms | 1 | 2022 | 205 | 0.650 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 13 | 0.650 |
Why?
|
| Tattooing | 1 | 2019 | 1 | 0.630 |
Why?
|
| Microscopic Angioscopy | 1 | 2019 | 1 | 0.630 |
Why?
|
| Capillaries | 1 | 2019 | 10 | 0.630 |
Why?
|
| Microcirculation | 1 | 2019 | 26 | 0.620 |
Why?
|
| Scleroderma, Systemic | 1 | 2019 | 8 | 0.620 |
Why?
|
| Skin Diseases | 1 | 2019 | 24 | 0.610 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2018 | 7 | 0.580 |
Why?
|
| Prospective Studies | 5 | 2023 | 1528 | 0.580 |
Why?
|
| Leukocytes | 1 | 2018 | 29 | 0.580 |
Why?
|
| Flow Cytometry | 1 | 2018 | 75 | 0.580 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 118 | 0.550 |
Why?
|
| Exercise | 3 | 2022 | 305 | 0.470 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 558 | 0.410 |
Why?
|
| Female | 10 | 2023 | 12677 | 0.380 |
Why?
|
| Male | 9 | 2023 | 12453 | 0.330 |
Why?
|
| Consensus | 3 | 2024 | 82 | 0.310 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1494 | 0.310 |
Why?
|
| Fatigue | 2 | 2023 | 53 | 0.260 |
Why?
|
| Pain | 3 | 2023 | 370 | 0.250 |
Why?
|
| Quality of Life | 4 | 2023 | 504 | 0.250 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 713 | 0.220 |
Why?
|
| Middle Aged | 6 | 2023 | 7555 | 0.220 |
Why?
|
| Lymphotoxin-alpha | 1 | 2024 | 2 | 0.220 |
Why?
|
| Global Health | 1 | 2024 | 29 | 0.220 |
Why?
|
| Chemokines | 1 | 2024 | 15 | 0.220 |
Why?
|
| Research Design | 1 | 2024 | 147 | 0.210 |
Why?
|
| Cytokines | 1 | 2024 | 167 | 0.200 |
Why?
|
| Monitoring, Ambulatory | 1 | 2022 | 16 | 0.190 |
Why?
|
| Physicians | 1 | 2023 | 103 | 0.190 |
Why?
|
| Muscles | 1 | 2022 | 48 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2022 | 58 | 0.180 |
Why?
|
| Biomarkers | 1 | 2024 | 453 | 0.180 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2021 | 13 | 0.180 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 63 | 0.180 |
Why?
|
| Attitude to Health | 1 | 2021 | 74 | 0.180 |
Why?
|
| Information Systems | 1 | 2021 | 23 | 0.180 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 1 | 0.170 |
Why?
|
| Gels | 1 | 2020 | 9 | 0.170 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 1 | 0.170 |
Why?
|
| Behcet Syndrome | 1 | 2020 | 4 | 0.170 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 37 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 13 | 0.170 |
Why?
|
| Prednisone | 1 | 2020 | 61 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 70 | 0.170 |
Why?
|
| Internship and Residency | 1 | 2023 | 189 | 0.160 |
Why?
|
| Demography | 1 | 2020 | 65 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 99 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 287 | 0.150 |
Why?
|
| Tissue Fixation | 1 | 2018 | 5 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 947 | 0.150 |
Why?
|
| Depressive Disorder | 1 | 2019 | 121 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2023 | 2960 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1122 | 0.140 |
Why?
|
| Aftercare | 1 | 2017 | 20 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 96 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 44 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 82 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2017 | 116 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2019 | 807 | 0.100 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 66 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 977 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2024 | 9 | 0.050 |
Why?
|
| Research Personnel | 1 | 2024 | 15 | 0.050 |
Why?
|
| Mentors | 1 | 2024 | 33 | 0.050 |
Why?
|
| Rituximab | 1 | 2023 | 40 | 0.050 |
Why?
|
| Faculty | 1 | 2023 | 23 | 0.050 |
Why?
|
| Emigrants and Immigrants | 1 | 2022 | 10 | 0.050 |
Why?
|
| Career Choice | 1 | 2022 | 25 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 32 | 0.050 |
Why?
|
| Self Report | 1 | 2023 | 174 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2023 | 334 | 0.050 |
Why?
|
| Equipment Design | 1 | 2021 | 104 | 0.050 |
Why?
|
| Exercise Test | 1 | 2021 | 56 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2023 | 184 | 0.040 |
Why?
|
| Infertility | 1 | 2020 | 6 | 0.040 |
Why?
|
| Child | 1 | 2024 | 990 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 201 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2020 | 3062 | 0.040 |
Why?
|
| Cerebral Angiography | 1 | 2019 | 21 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 84 | 0.040 |
Why?
|
| Aged | 2 | 2023 | 7669 | 0.040 |
Why?
|
| United States | 1 | 2022 | 1726 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 124 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 554 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1220 | 0.030 |
Why?
|
| Risk Factors | 1 | 2017 | 1942 | 0.020 |
Why?
|